ReviewJournal of neuro-oncology2017
Advancements in the study of miRNA regulation during the cell cycle in human pituitary adenomas.
Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- Loss of miR-101-3p in melanoma stabilizes genomic integrity, leading to cell death prevention.Cellular & molecular biology letters · 2024Article
- miRNA dysregulation is an emerging modulator of genomic instability.Seminars in cancer biology · 2021Review
- Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.Frontiers in endocrinology · 2021Review
- Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.Endocrine reviews · 2020Review
- The Genetics of Pituitary Adenomas.Journal of clinical medicine · 2019Review
- Article
- Roles of differential expression of miR-543-5p in GH regulation in rat anterior pituitary cells and GH3 cells.PloS one · 2019Article
- Recent advances in understanding corticotroph pituitary tumor initiation and progression.F1000Research · 2018Review
- Knockdown of long non-coding RNAInternational journal of clinical and experimental pathology · 2018Article
- Low expression of miRNA-1290 associated with local invasion and recurrence in sacral chordoma.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pituitary adenomas (PAs), single-clone adenomas arising from pituitary gland cells, comprise one of the most frequent tumors found in the sella region. The prevalence of PAs is approximately 15%, third only after gliomas and meningioma among intracranial tumors. Autopsy and radiological analysis found that the incidence of PAs is approximately 22.5%. Most PAs are benign, although a few are malignant. Just 0.1% of patients with PAs develop pituitary carcinoma. However, owing to mass effects and unregulated secretion of pituitary hormones, PAs also lead to serious morbidity. The low rate of diagnosis at onset and the lack of effective treatments for patients with recurrent disease increase the morbidity rates. Therefore, there is an urgent need to ascertain the pathological mechanism of PAs for improved diagnosis and development of specific therapies. At present, the pathogenesis of PAs is poorly understood; however, disruption of the cell cycle is known to play an important role. MicroRNAs are short noncoding RNAs that regulate gene expression at the post-transcriptional level and play a role in regulating genes involved in carcinogenesis or tumor suppression. Previous studies have demonstrated a strong connection between dysregulation of microRNAs and dysregulation of the cell cycle in PAs. In this review, we summarize the recent progress in the study of microRNA dysregulation resulting in disruption of the cell cycle in PAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.